Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

263 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin JA, Miller WH Jr, Italiano A, Kao S, Piha-Paul SA, Delord JP, McWilliams RR, Fabrizio DA, Aurora-Garg D, Xu L, Jin F, Norwood K, Bang YJ. Marabelle A, et al. Among authors: miller wh jr. Lancet Oncol. 2020 Sep 10:S1470-2045(20)30445-9. doi: 10.1016/S1470-2045(20)30445-9. Online ahead of print. Lancet Oncol. 2020. PMID: 32919526
The MNK1/2-eIF4E Axis as a Potential Therapeutic Target in Melanoma.
Prabhu SA, Moussa O, Miller WH Jr, Del Rincón SV. Prabhu SA, et al. Among authors: miller wh jr. Int J Mol Sci. 2020 Jun 5;21(11):4055. doi: 10.3390/ijms21114055. Int J Mol Sci. 2020. PMID: 32517051 Free PMC article. Review.
A review of cancer immunotherapy: from the past, to the present, to the future.
Esfahani K, Roudaia L, Buhlaiga N, Del Rincon SV, Papneja N, Miller WH Jr. Esfahani K, et al. Among authors: miller wh jr. Curr Oncol. 2020 Apr;27(Suppl 2):S87-S97. doi: 10.3747/co.27.5223. Epub 2020 Apr 1. Curr Oncol. 2020. PMID: 32368178 Free PMC article. Review.
Moving towards personalized treatments of immune-related adverse events.
Esfahani K, Elkrief A, Calabrese C, Lapointe R, Hudson M, Routy B, Miller WH Jr, Calabrese L. Esfahani K, et al. Among authors: miller wh jr. Nat Rev Clin Oncol. 2020 Aug;17(8):504-515. doi: 10.1038/s41571-020-0352-8. Epub 2020 Apr 3. Nat Rev Clin Oncol. 2020. PMID: 32246128 Review.
MNK1 signaling induces an ANGPTL4-mediated gene signature to drive melanoma progression.
Yang W, Khoury E, Guo Q, Prabhu SA, Emond A, Huang F, Gonçalves C, Zhan Y, Plourde D, Nichol JN, Dahabieh MS, Miller WH Jr, Del Rincón SV. Yang W, et al. Among authors: miller wh jr. Oncogene. 2020 Apr;39(18):3650-3665. doi: 10.1038/s41388-020-1240-5. Epub 2020 Mar 4. Oncogene. 2020. PMID: 32132651
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies.
Chung HC, Piha-Paul SA, Lopez-Martin J, Schellens JHM, Kao S, Miller WH Jr, Delord JP, Gao B, Planchard D, Gottfried M, Zer A, Jalal SI, Penel N, Mehnert JM, Matos I, Bennouna J, Kim DW, Xu L, Krishnan S, Norwood K, Ott PA. Chung HC, et al. Among authors: miller wh jr. J Thorac Oncol. 2020 Apr;15(4):618-627. doi: 10.1016/j.jtho.2019.12.109. Epub 2019 Dec 20. J Thorac Oncol. 2020. PMID: 31870883
A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors.
Abdul Razak AR, Miller WH Jr, Uy GL, Blotner S, Young AM, Higgins B, Chen LC, Gore L. Abdul Razak AR, et al. Among authors: miller wh jr. Invest New Drugs. 2020 Aug;38(4):1156-1165. doi: 10.1007/s10637-019-00869-2. Epub 2019 Nov 16. Invest New Drugs. 2020. PMID: 31734832
Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
Ribas A, Lawrence D, Atkinson V, Agarwal S, Miller WH Jr, Carlino MS, Fisher R, Long GV, Hodi FS, Tsoi J, Grasso CS, Mookerjee B, Zhao Q, Ghori R, Moreno BH, Ibrahim N, Hamid O. Ribas A, et al. Among authors: miller wh jr. Nat Med. 2019 Aug;25(8):1319. doi: 10.1038/s41591-019-0535-y. Nat Med. 2019. PMID: 31267021
A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy.
Kumar R, de Vijver MV, Tortora G, Ciardiello F, Goldkorn T, Miller WH Jr, Norton L. Kumar R, et al. Among authors: miller wh jr. Cancer Res. 2019 Sep 1;79(17):4315-4323. doi: 10.1158/0008-5472.CAN-19-0989. Epub 2019 Jun 18. Cancer Res. 2019. PMID: 31213466 Review.
Translation of cancer immunotherapy from the bench to the bedside.
Guo Q, Huang F, Goncalves C, Del Rincón SV, Miller WH Jr. Guo Q, et al. Among authors: miller wh jr. Adv Cancer Res. 2019;143:1-62. doi: 10.1016/bs.acr.2019.03.001. Epub 2019 May 2. Adv Cancer Res. 2019. PMID: 31202357 Review.
263 results
Jump to page
Feedback